Jco Precision Oncology
Overview
Jco Precision Oncology is a scientific journal, published since 2017 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
JCO Precis Oncol
Start
2017
End
Continuing
e-ISSN
2473-4284
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 7562
48
SJR / Ranks: 976
2249
CiteScore / Ranks: 2159
8.20
JIF / Ranks: 1820
4.6
Recent Articles
21.
Feng F, Smith M, Saad F, Mobadersany P, Tian S, Yip S, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400653.
PMID: 39889245
Purpose: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital...
22.
Nguyen-Hoang N, Liu Y, Henry N, Pai M, Zhu H, Hertz D
JCO Precis Oncol
. 2025 Jan;
9:e2400380.
PMID: 39889244
Purpose: Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting toxicity of paclitaxel in patients with cancer. TIPN prediction is challenging although patients with higher systemic paclitaxel exposure have higher TIPN risk....
23.
24.
Heeke A, Elliott A, OKeefe K, Livasy C, Symanowski J, Steiner M, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2300719.
PMID: 39889242
Purpose: Alterations in human epidermal growth factor receptor 2 (HER2; gene) may be clinically relevant when considering HER2-targeted therapies. We have characterized the breadth of alterations (mutation, fusion, and copy...
25.
Kim S, Itani M, Liu X, Sun L, Krysiak K, Fox N, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400305.
PMID: 39889241
No abstract available.
26.
Dupont W, Jones A, Smith J
JCO Precis Oncol
. 2025 Jan;
9:e2400569.
PMID: 39874495
Purpose: Considerable genetic heterogeneity is currently thought to underlie hereditary prostate cancer (HPC). Most families meeting criteria for HPC cannot be attributed to currently known pathogenic variants. Methods: To discover...
27.
Park J, Ahn J, Merkin R, Patel M, Wirth L, Roberts T
JCO Precis Oncol
. 2025 Jan;
9():e2400741.
PMID: 39869839
Purpose: Immune checkpoint inhibitors (ICIs) are now first-line therapy for most patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and cetuximab is most often used as subsequent...
28.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400199.
PMID: 39869838
Purpose: MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy...
29.
Rha S, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas D, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400710.
PMID: 39854659
Purpose: Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction cancer (GC). We assessed FGFR2b protein overexpression prevalence in...
30.
Luen S, Brown L, van Geelen C, Savas P, Kammler R, DellOrto P, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400599.
PMID: 39854658
Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. Methods: This study included HR+, HER2-negative...